LILLY FRANCE
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1962-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- https://www.lilly.fr
Clinical Trials
0
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
41
NMPA:38
SFDA:3
Drug Approvals
Gemcitabine Hydrochloride for Injection
- Product Name
- 健择
- Approval Number
- 国药准字HJ20160224
- Approval Date
- Dec 28, 2022
NMPA
Gemcitabine Hydrochloride for Injection
- Product Name
- 健择
- Approval Number
- 国药准字HJ20160225
- Approval Date
- Dec 28, 2022
NMPA
Isophane Protamine Human Insulin Injection
- Product Name
- 优泌林
- Approval Number
- 国药准字SJ20160050
- Approval Date
- Aug 27, 2021
NMPA
Isophane Protamine Human Insulin Injection
- Product Name
- 优泌林
- Approval Number
- 国药准字SJ20160049
- Approval Date
- Aug 27, 2021
NMPA
Isophane Protamine Human Insulin Injection
- Product Name
- 优泌林
- Approval Number
- 国药准字SJ20160048
- Approval Date
- Aug 27, 2021
NMPA
Isophane Protamine Human Insulin Injection
- Product Name
- 优泌林
- Approval Number
- 国药准字SJ20160051
- Approval Date
- Aug 27, 2021
NMPA
Mixed Protamine Human Insulin Injection (30R)
- Product Name
- 优泌林 70/30
- Approval Number
- 国药准字SJ20160045
- Approval Date
- Aug 23, 2021
NMPA
- Prev
- 1
- 2
- 3
- 4
- Next
Clinical Trials
No trials found
News
No news found